GenomeDx, Astellas work to identify genomic drivers of Xtandi response

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

GenomeDx Biosciences and Astellas announced a collaboration to apply genomic tumor profiling using GenomeDx’s Decipher Classifier and Decipher GRID as a potential aid in identifying prostate cancer patients undergoing active surveillance who may benefit from treatment with enzalutamide (Xtandi).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login